The honest bottom line first: BPC-157 has no established human dosing standard, because it has not completed the controlled human trials that would define one, and it holds no regulatory approval as a therapeutic. Nearly the entire published record describes what investigators have done in rats and mice, where the lyophilized peptide is reconstituted in a sterile diluent and given by injection most often, at doses expressed per kilogram of body weight rather than as fixed amounts. Any figure that touches on a human-relevant number in this literature is reached through allometric scaling, not clinical dosing, and stands at the preclinical level of evidence.
BPC-157 is an investigational compound with no FDA-approved human dosing standard, and its entire reported dosing record describes preclinical experiments in animals at microgram-per-kilogram and nanogram-per-kilogram amounts.
Injection carries most of the reported routes, with intraperitoneal and intramuscular delivery the two most common in rodent work because they give reliable systemic exposure and reproducible dosing in small animals. What sets this peptide apart is a documented line of intragastric and drinking-water studies, which investigators cite as evidence that BPC-157 retains activity after exposure to the gastrointestinal environment, a property many peptides lack. Route selection tracks the model: a gut-injury study tends toward oral or intragastric delivery, while a tendon or muscle model leans on local or intramuscular routes.
Intraperitoneal and intramuscular injection are the most frequently reported routes in the animal literature, while documented intragastric and drinking-water delivery is cited as evidence that BPC-157 retains activity after gastrointestinal exposure.
Reported doses cluster in the microgram-per-kilogram and nanogram-per-kilogram bands, with a figure near 10 mcg/kg recurring across many rodent studies as a representative amount. The units shift between labs because investigators express the dose relative to body weight rather than as a fixed quantity, working in nanograms, micrograms, or occasionally milligrams per kilogram depending on the concentration and the endpoint. Across the whole record the span between lowest and highest reported doses covers several orders of magnitude, a reflection of how many different models are in play rather than disagreement over a single correct amount.
The animal literature reports BPC-157 doses spanning several orders of magnitude in nanogram-per-kilogram to milligram-per-kilogram terms, with roughly 10 micrograms per kilogram recurring as the most-cited representative rodent dose and no single canonical value across models.
Doses are normalized to body weight because the same fixed amount would mean very different exposures in animals of different sizes, so an amount per kilogram lets researchers compare protocols and reproduce conditions across studies and species. In a rat weighing a few hundred grams, 10 mcg/kg works out to only a few micrograms of actual peptide per administration, which explains why such small absolute quantities recur throughout the record. When the literature reaches toward a larger species, it invokes allometric scaling, which adjusts for metabolic rate and body surface area rather than scaling linearly by weight, a distinction that matters because naive linear scaling overstates the equivalent dose and ignores species differences in metabolism, distribution, and clearance.
Study protocols express BPC-157 doses per kilogram of body weight and rely on allometric scaling rather than linear weight conversion when extrapolating to larger species, because naive linear scaling overstates the equivalent dose and ignores species differences in metabolism and clearance.
The peptide arrives as a lyophilized, freeze-dried powder and is reconstituted in a sterile diluent, most often bacteriostatic or sterile water and in some protocols saline, before any dosing takes place. Once dissolved the stock holds a known concentration, and a working dose is calculated by relating the volume drawn to that concentration and to the animal's weight, which is how very small per-kilogram doses are achieved with manageable injection volumes. Small handling errors, such as miscalculating concentration, introducing air, or degrading the peptide through poor storage, can change the dose actually delivered, so careful preparation is itself a methodological variable.
Laboratory protocols reconstitute lyophilized BPC-157 in a sterile diluent such as bacteriostatic water before dosing, then calculate the working dose from the known stock concentration and the animal's weight, treating sterile technique and accurate concentration as methodological variables that affect the delivered dose.
Schedules in the record run from a single acute administration, used to probe an immediate effect, out to repeated dosing sustained across a defined treatment window, with once-daily regimens a frequent pattern. The model sets the schedule: an acute injury study tends to concentrate dosing in the early phase after injury, while a chronic or progressive model extends dosing across a longer observation period. Studies of tendon, muscle, or gut injury commonly dose daily for a span of days to a few weeks until the relevant endpoint is assessed, and some designs use continuous or quasi-continuous delivery through drinking water that spreads exposure across the day.
Across the animal literature BPC-157 dosing frequency ranges from single acute administrations to once-daily regimens sustained for days to a few weeks, with the schedule set by the injury or disease model being measured rather than any human treatment standard.
Local administration aims to concentrate exposure where the peptide is presumed to act, delivering it at or very near a wound, tendon, or other injured tissue rather than relying on systemic distribution to reach the site. Models with discrete, accessible injuries, such as tendon transection, muscle damage, or surface wounds, tend to favor local delivery because the target is localized and the route can be applied directly. The record reports that both local and systemic dosing produce measurable effects in their respective models, and some studies compare the two to ask whether direct application offers an advantage, while local delivery's practical limits make systemic routes more convenient for many designs.
| Criteria | Local administration | Systemic administration |
|---|---|---|
| Aim | Concentrate exposure at the injured site | Distribute the peptide throughout the body |
| Best-suited models | Discrete, accessible injuries (tendon transection, surface wounds) | Diffuse or internal injury, general designs |
| Practical limits | Small volumes, hard to reach internal tissue, hard to standardize placement | More convenient and reproducible across designs |
| Reported effect | Measurable in its models | Measurable in its models |
Both local and systemic dosing produce measurable effects in their respective animal models, with local delivery suited to discrete accessible injuries and systemic routes preferred for diffuse or internal targets and for ease of standardization.
Stability considerations begin before any dosing: the lyophilized powder is typically stored cold and dry, with freezing common for long-term holding and refrigeration for shorter periods. Once reconstituted, the aqueous solution is generally kept refrigerated and used within a limited window, because peptides in solution degrade faster than in dry form and warm temperatures accelerate the breakdown. Degradation matters for dosing because a partially broken-down stock delivers less intact peptide than its nominal concentration implies, so a dose calculated from the labeled amount can overstate what actually reaches the subject.
Storage temperature, time in solution, and diluent choice are documented as methodological variables that can lower the effective dose of BPC-157, because a partially degraded stock delivers less intact peptide than its nominal concentration implies.
When the literature touches human-relevant figures, it leans on allometric or body-surface-area scaling to turn a per-kilogram animal dose into a rough human-equivalent estimate, an approach borrowed from general pharmacology rather than from any compound-specific human data. The central caveat is that BPC-157 has no established human dosing standard, because it has not completed the controlled human trials that would define a safe and effective dose and lacks regulatory approval as a therapeutic. Any extrapolated number rests on assumptions about absorption, distribution, metabolism, and clearance in a human body, none of which are well characterized, so even a carefully scaled figure carries wide uncertainty.
BPC-157 has no established human dosing standard because it has not completed controlled human trials and lacks regulatory approval, so any animal-to-human dose translation in the literature is an allometric estimate carrying wide uncertainty, not validated dosing.
Educational use only. This article describes what the published scientific and clinical literature reports about BPC-157. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
